CytomX Therapeutics, Inc. Operating Lease, Liability, Noncurrent
CytomX Therapeutics, Inc. (CTMX) had Operating Lease, Liability, Noncurrent of $4.21 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-06
- 2026-06-30: Operating Lease, Liability, Noncurrent $4.21M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $0.00.
- 2025-09-30: Operating Lease, Liability, Noncurrent $0.00.
- 2025-06-30: Operating Lease, Liability, Noncurrent $1.44M.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $4.21M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.44M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $2.86M 10-Q · filed 2025-05-12 | |
| 2024-12-31 | $4.24M 10-K · filed 2026-03-16 | |
| 2024-09-30 | $5.60M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $6.88M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $8.15M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $9.38M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $10.60M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $11.75M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $12.87M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $13.97M 10-K · filed 2024-03-11 | |
| 2022-09-30 | $15.05M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $16.08M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $17.08M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $18.06M 10-K/A · filed 2023-03-27 | |
| 2021-09-30 | $19.02M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $19.92M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $20.81M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $21.68M 10-K/A · filed 2023-03-27 | |
| 2020-09-30 | $22.52M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $23.32M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $24.11M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $24.87M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $25.62M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $26.32M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $24.87M 10-Q · filed 2020-05-07 | $27.01M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |